Tumor "age" in early-onset colorectal cancer
- PMID: 39919707
- DOI: 10.1016/j.cell.2024.12.003
Tumor "age" in early-onset colorectal cancer
Abstract
The incidence of early-onset colorectal cancer (EO-CRC) is surging, and by 2030, one-third of all CRCs will occur before the commonly recommended screening age of 50 years. The time required for EO-CRC to reach the metastatic stage is unknown, yet this knowledge is critical to tailor early-diagnosis screening strategies. Here, we discuss how defining a key biological feature of EO-CRC may be central to protecting young adults from an alarming and probably unprecedented tumor epidemic.
Copyright © 2024 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests A.B. reports receipt of grants/research support from Neophore, AstraZeneca, and Boehringer Ingelheim and honoraria/consultation fees from Guardant Health. A.B. is a stock shareholder of Neophore and Kither Biotech. A.B. is an advisory board member for Neophore. S.S. is an advisory board member for Agenus, AstraZeneca, Bayer, Bristol Myers Squibb, CheckmAb, Daiichi-Sankyo, GlaxoSmithKline, MSD, Merck, Novartis, Pierre-Fabre, Seagen, and T-One Therapeutics.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical